Page 6 - ேசை இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
FDA Approves KEYTRUDA® Plus LENVIMA® Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.
Doctors Weigh Prescribing Controversial Alzheimer s Drug
theepochtimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theepochtimes.com Daily Mail and Mail on Sunday newspapers.
Biogen Partner Pushing On With Alzheimer’s Drug Despite Fracas
Bloomberg 7 hrs ago © Bloomberg Biogen Partner Pushing On With Second Drug Despite Controversy
(Bloomberg) Fresh off the historic but controversial approval of its Alzheimer’s drug Aduhelm with Biogen Inc. in the U.S., Japanese pharmaceutical company Eisai Co. says it’s pushing ahead with its second therapy to combat the disease, which has shown fewer side effects and could come in a more convenient form for patients.
The Tokyo-based company’s plans for the second drug come amid renewed scrutiny around the U.S. Food and Drug Administration’s June approval of Aduhelm, which caused resignations among a panel of independent experts who said the therapy was ineffective, and has garnered a call for a federal probe in the U.S.
The Tokyo-based company’s plans for the second drug come amid renewed scrutiny around the U.S. Food and Drug Administration’s June approval of Aduhelm, which caused resignations among a panel of independent experts who said the therapy was ineffective, and has garnered a call for a federal probe in the U.S.
Eisai’s second compound in development to treat Alzheimer’s has the potential for fewer side effects like brain swelling and bleeding and could come in an injection enabling at-home administration, rather than intravenous infusions in hospitals, Ivan Cheung, the Woodcliff Lake, New Jersey-based global president of Eisai’s neurology business, told Bloomberg News in an interview last week. The second drug, known as lecanemab or BAN2401, works similarly to Aduhelm by reducing amyloid plaques from the brains of Alzheimer’s patients.
Eisai pushes second Alzheimer s drug despite call to probe U S approval of first
japantimes.co.jp - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from japantimes.co.jp Daily Mail and Mail on Sunday newspapers.